{
    "nct_id": "NCT06806930",
    "official_title": "Predicting Response to Neoadjuvant Endocrine Therapy (Neo-PREDICT)",
    "inclusion_criteria": "* Be capable of understanding the investigational nature of the study and all pertinent aspects of the study\n* Be capable of signing and providing written consent in accordance with institutional and federal guidelines\n* Histologically or cytologically confirmed diagnosis of invasive carcinoma of the breast\n* Clinical stage 1 to 3 breast cancer\n* Candidate for surgical resection\n* Estrogen receptor > 10% positive stained cells based on most recent tumor biopsy and documented by a local laboratory or medical record.\n* HER2 negative or HER2 low breast cancer based on the most recent tumor biopsy and documented by a local laboratory or medical record. HER2 negative tumor is defined per American Society of Clinical Oncology and the College of American Pathologists guidelines, 2018. Patients with HER2 low tumors are eligible as long as patients are not candidates for any HER2 directed therapy.\n* Ability to take oral medication\n* Be willing and able to comply with scheduled visits, treatment plan, and follow up with research staff\n* Age â‰¥ 21 years\nHealthy volunteers allowed\nMust have minimum age of 21 Years",
    "exclusion_criteria": "* Inability to comply taking NET\n* Inability to comply to study procedures",
    "miscellaneous_criteria": ""
}